SynthesisBMC nephrology2025
The therapeutic effect of Berberine on rodent models of kidney injury: a systematic review and meta - analysis.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Berberine Attenuates Cadmium-Induced Nephrotoxicity by Suppressing LDHA-Mediated Glycolytic Reprogramming and Restoring Mitochondrial TCA Cycle Metabolism.Biomolecules · 2026Article
- Berberine in oral diseases: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBerberine, a potent bioactive compound extracted from the traditional herbal medicine Huanglian (Coptis chinensis), has garnered significant attention due to its diverse pharmacological effects, particularly in the treatment of renal diseases. Previous studies have highlighted berberine's therapeutic potential in ameliorating acute kidney injury (AKI) in murine animal models, suggesting its prospective use as a renal protective agent. Its mechanisms involve antioxidant and anti-inflammatory pathways, which are key to its effects.
methodsThis systematic review and meta-analysis aimed to elucidate the effects and underlying biological mechanisms of berberine in murine models of AKI. To ensure comprehensive coverage, an exhaustive literature search was conducted across reputable databases, including PubMed, Web of Science, Cochrane Library, Ovid, and Embase. The search was performed in December 2024 and no limitations were applied regarding the publication date of the studies. The SYRCLE's risk of bias tool was employed for a rigorous quality assessment of each study. Statistical analyses were performed using Revman5.4.2 and STATA 15.1 software to ensure the accuracy and reliability of data interpretation.
resultsWe included a total of 19 relevant studies, Our research indicates that the animal studies included in our review demonstrate a significant improvement in renal function metrics of blood specimens in rodent models. The standard mean difference (SMD) for blood urea nitrogen (BUN) is - 3.31 (95% CI: - 4.19, - 2.42), and for Serum Creatinine (SCR) it's - 2.67 (95% CI: - 3.26, - 2.09), highlighting berberine's significant renal protective effects. Additionally, berberine favorably affects inflammatory markers, with SMD for IL - 18 at - 1.30 (95% CI: - 2.76, - 0.16) and for TNF - α at - 3.90 (95% CI: - 6.19, - 1.61).Berberine significantly reduced BUN and SCR.
conclusionThe beneficial effects of berberine in AKI are likely attributed to its diverse mechanisms, including antioxidant, anti-inflammatory pathways. However, to accurately delineate the efficacy and safety of berberine as a therapeutic intervention for AKI, future research should prioritize large-scale, long-term, and high-quality preclinical trials. Such endeavors are critical for validating our findings and establishing a solid foundation for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.